BTIG initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $45 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment
- Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results
- ArriVent Biopharma initiated with a Buy at Truist
- ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target
- ArriVent Biopharma management to meet virtually with Clear Street